Alder BioPharmaceuticals Inc. (ALDR) expects top-line 12-week data from an ongoing 600-patient phase 2b double-blind trial of ALD403 in chronic migraine patients in the second half of 2015.
The first of the two pivotal studies of ALD403 in migraine patients is planned for initiation in the second half of 2015.
ALDR closed Wednesday's trading at $44.74, down 0.95%.
Allergan plc. (AGN) has received FDA approval to market 28 additional styles of Natrelle 410 silicone-filled breast implants, including extra-full projection styles and additional low projection, low height styles.
The Natrelle 410 Shaped Gel Breast Implants, which received the first FDA approval in February 2013, are filled with a highly cohesive silicone gel enabling the implants to have long-lasting shape over time.
The newly approved additional implant styles will be available to surgeons and patients in October 2015, said the company.
AGN closed Wednesday's trading at $336.64, up 1.70%.
Biocept Inc. (BIOC) has launched its first liquid biopsy diagnostic test - Target Selector - for colorectal cancer. The new test uses patient's blood sample to detect KRAS, predictive biomarker for solid tumor cancers.
BIOC closed Wednesday's trading at $2.40, up 1.27%.
Shares of medical device company DexCom Inc. (DXCM) touched a new high on Wednesday after the company reported better-than-expected revenue for the second quarter of 2015.
Total revenue grew to $93.2 million for the second quarter of 2015, an increase of 59% from the same quarter in 2014, and well above analysts' expectations of $84.81 million.
The company's net loss for Q2, 2015 narrowed to $3.7 million or $0.05 per share from $6.0 million or $0.09 per share in the year-ago quarter. Analysts polled by Thomson Reuters expected the company to report a loss of $0.03 per share.
DXCM touched a new high of $87 on Wednesday before closing the day's trading at $85.95, up 1.20%.
InspireMD Inc. (NSPR) has entered into a partnership with Penumbra Inc. to distribute its carotid CGuard EPS through their direct commercialization team.
The CGuard Embolic Prevention System (EPS) is CE Mark approved but is not approved for sales in the U.S. by the FDA at this time.
NSPR closed Wednesday's trading at $0.25, down 10.71%.
MacroGenics Inc. (MGNX), which has initiated a phase III study of Margetuximab in metastatic breast cancer patients, plans to enroll 530 patients in the study. The study, dubbed SOPHIA, is expected to be completed in roughly three years.
The company remains on track to initiate a phase 1/2 combination study of Margetuximab in gastroesophageal cancer starting in the fourth quarter of 2015.
A phase I study of MGA271 in combination with pembrolizumab in patients with melanoma, non-small cell lung carcinoma and squamous cell carcinoma of the head and neck is planned for this quarter.
MGNX closed Wednesday's trading at $37.88, up 0.53%.
For comments and feedback contact: editorial@rttnews.com
Business News